Stephen J Bagley, Zev A Binder, Lamia Lamrani, Eliana Marinari, Arati S Desai, MacLean P Nasrallah, Eileen Maloney, Steven Brem, Robert A Lustig, Goldie Kurtz, Michelle Alonso-Basanta, Pierre-Emmanuel Bonté, Christel Goudot, Wilfrid Richer, Eliane Piaggio, Shawn Kothari, Lea Guyonnet, Coralie L Guerin, Joshua J Waterfall, Suyash Mohan, Wei-Ting Hwang, Oliver Y Tang, Meghan Logun, Meghna Bhattacharyya, Kelly Markowitz, Devora Delman, Amy Marshall, E John Wherry, Sebastian Amigorena, Gregory L Beatty, Jennifer L Brogdon, Elizabeth Hexner, Denis Migliorini, Cecile Alanio, Donald M O'Rourke
We previously showed that chimeric antigen receptor (CAR) T-cell therapy targeting epidermal growth factor receptor variant III (EGFRvIII) produces upregulation of programmed death-ligand 1 (PD-L1) in the tumor microenvironment (TME). Here we conducted a phase 1 trial (NCT03726515) of CAR T-EGFRvIII cells administered concomitantly with the anti-PD1 (aPD1) monoclonal antibody pembrolizumab in patients with newly diagnosed, EGFRvIII+ glioblastoma (GBM) (n = 7). The primary outcome was safety, and no dose-limiting toxicity was observed...
January 12, 2024: Nature Cancer